BFBIO 1QFY27 profit rises 16%

Mettis Global reported on October 28 that BF Biosciences Limited earned Rs184.88 million in the three months ending September 30, 2026, up 15.9% from Rs159.52 million a year earlier. Earnings per share reached Rs2.09, compared with Rs1.81 in the same quarter of the prior fiscal year. Quarterly revenue advanced 14.5% to Rs2.78 billion.

Gross profit climbed 23.7% to Rs1.28 billion as the cost of goods sold increased by 7.6%, lifting the gross margin to 46.14% from 42.69%. However, selling and distribution expenses rose 22.1%, administrative costs grew 86.5%, and other income fell 72.7% to Rs9.51 million. Operating profit still expanded 9.1% to Rs324.09 million, while finance costs increased 14% and income tax was nearly unchanged at Rs109.12 million. The quarterly results show stronger earnings alongside rising operating expenses for the pharmaceutical company.